Lisa Bonadonna  completed her PhD in Immunology at the University of Melbourne, then she entered the pharmaceutical industry holding a range of senior medical, research and commercial positions covering many geographies. 

In 2009, as Vice President of the Adult Vaccine Portfolio, she led GSK’s Vaccines H1N1 pandemic response and subsequently negotiated the first industry agreement signed with the WHO under the Pandemic Influenza Preparedness Framework.

Dr Bonadonna has an MBA and an MSc in Health Policy, including a dissertation on access to medicines. In 2021 Lisa joined the Coalition for Epidemic Preparedness Innovations (CEPI) to contribute her expertise in tackling the COVID-19 pandemic with a particular focus on Africa.  Most recently Lisa has been working with South Africa’s Aspen Pharmacare assisting with their foray into biologicals and vaccines.

Lisa is currently an active member of AVMI’s Market Shaping Working Group.